Insys Therapeutics Inc (INSY) Price Target Lowered to $14.00 at Jefferies Group LLC

Insys Therapeutics Inc (NASDAQ:INSY) had its target price cut by research analysts at Jefferies Group LLC from $16.00 to $14.00 in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 34.36% from the stock’s previous close.

Several other equities research analysts also recently issued reports on INSY. Royal Bank of Canada restated a “buy” rating and set a $23.00 price objective on shares of Insys Therapeutics in a report on Friday, December 9th. Zacks Investment Research upgraded Insys Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 4th. Finally, Oppenheimer Holdings Inc. reiterated a “” rating on shares of Insys Therapeutics in a research report on Thursday, January 19th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $18.00.

Insys Therapeutics (NASDAQ:INSY) traded down 2.50% on Tuesday, hitting $10.16. 220,661 shares of the stock were exchanged. The stock’s 50 day moving average price is $10.72 and its 200 day moving average price is $10.94. Insys Therapeutics has a 52-week low of $8.70 and a 52-week high of $19.96. The firm has a market cap of $731.08 million, a PE ratio of 101.60 and a beta of 0.26.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings data on Monday, April 3rd. The specialty pharmaceutical company reported $0.03 earnings per share (EPS) for the quarter. Insys Therapeutics had a return on equity of 9.39% and a net margin of 8.71%. The company had revenue of $54.86 million for the quarter, compared to the consensus estimate of $52.08 million. During the same period in the previous year, the business earned $0.42 EPS. Insys Therapeutics’s revenue for the quarter was down 41.6% compared to the same quarter last year. Equities research analysts forecast that Insys Therapeutics will post ($0.34) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/04/21/jefferies-group-llc-cuts-insys-therapeutics-inc-insy-price-target-to-14-00-updated.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. Menora Mivtachim Holdings LTD. bought a new position in Insys Therapeutics during the fourth quarter worth about $119,000. Stevens Capital Management LP acquired a new stake in shares of Insys Therapeutics during the third quarter valued at $147,000. Bank of Montreal Can increased its stake in shares of Insys Therapeutics by 215.3% in the first quarter. Bank of Montreal Can now owns 20,812 shares of the specialty pharmaceutical company’s stock valued at $219,000 after buying an additional 14,212 shares during the last quarter. Acrospire Investment Management LLC increased its stake in shares of Insys Therapeutics by 49.1% in the third quarter. Acrospire Investment Management LLC now owns 25,495 shares of the specialty pharmaceutical company’s stock valued at $301,000 after buying an additional 8,400 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in shares of Insys Therapeutics by 34.9% in the third quarter. Alps Advisors Inc. now owns 30,275 shares of the specialty pharmaceutical company’s stock valued at $357,000 after buying an additional 7,826 shares during the last quarter. Institutional investors own 45.21% of the company’s stock.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

5 Day Chart for NASDAQ:INSY

Receive News & Ratings for Insys Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply